Početna stranicaWXXWY • OTCMKTS
add
Wuxi Biologics Cayman ADR
Preth. zaklj. cijena
2,77 $
Dnevni raspon
2,72 $ - 2,76 $
Godišnji raspon
2,69 $ - 13,25 $
Tržišna kapitalizacija
48,43 mlr. HKD
Prosječna količina
85,57 tis.
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (CNY) | pro 2023.info | Godišnja promjena |
|---|---|---|
Prihod | 4,27 mlr. | 5,95 % |
Operativni troškovi | 818,44 mil. | 13,31 % |
Neto dohodak | 566,53 mil. | −39,90 % |
Neto profitabilnost | 13,26 | −43,28 % |
Zarada po dionici | — | — |
EBITDA | 1,06 mlr. | −1,78 % |
Efektivna porezna stopa | 25,05 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (CNY) | pro 2023.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 11,24 mlr. | 29,02 % |
Ukupna imovina | 56,58 mlr. | 14,15 % |
Ukupne obveze | 12,56 mlr. | −5,94 % |
Ukupni kapital | 44,02 mlr. | — |
Dionice u optjecaju | 4,22 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,29 | — |
Povrat imovine | 3,60 % | — |
Povrat kapitala | 4,19 % | — |
Tok novca
Neto promjena novca
| (CNY) | pro 2023.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 566,53 mil. | −39,90 % |
Gotovina od poslovanja | — | — |
Gotovina iz ulaganja | — | — |
Gotovina iz financiranja | — | — |
Neto promjena novca | — | — |
Slobodan tok novca | — | — |
Više
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Glavni izvršni direktor
Osnovano
2010
Web-lokacija
Zaposlenici
12.740
